Bromhexine is almost completely metabolized and is a Cyp3A4 substrate. It is not listed as an inducer or MBI of CYPs and in therapeutic use no drug-drug interactions involving CYP enzymes has been observed.

Bromhexine is indicated for respiratory disorders with viscous mucus.

Bromhexine is almost completely metabolized. The half-life elimination is 1 hour. Ambroxol is a metabolite of bromhexine and in vitro studies have shown that it is metabolized by CYP3A4 (Ischiguro 2000). In vitro studies have also shown that ambroxol is a weak inhibitor (Ischiguro 2000), which indicates that the potential for drug-drug interactions is low (Ischiguro 2000 and Malerba 2008). The Summary of Product Characteristics also states that interactions with CYP2C9 and CYP3A4 are unlikely and in pharmacotherapeutic use no clinically significant DDIs has been observed (DRUID, Interaktionsdatabasen). This indicates that bromhexine or its metabolites do not act as inducers or inhibitors of CYP enzymes in vivo.

Uneventful use reported in 9 patients with acute porphyria.